What is the official website of Novartis Italia ?

The official website of Novartis Italia is https://www.novartis.it/.

What is Novartis Italia's cybersecurity risk score?

Novartis Italia has an AI-generated cybersecurity risk score of 758 out of 1000, indicating a Fair security posture according to Rankiteo's assessment.

How many security incidents has Novartis Italia experienced?

According to Rankiteo, Novartis Italia currently holds 0 security badges, indicating that no recognized compliance certifications are currently verified for the organization.

Has Novartis Italia been affected by any supply chain cyber incidents ?

According to Rankiteo, Novartis Italia has not been affected by any supply chain cyber incidents, and no incident IDs are currently listed for the organization.

Does Novartis Italia have SOC 2 Type 1 certification ?

According to Rankiteo, Novartis Italia is not certified under SOC 2 Type 1.

Does Novartis Italia have SOC 2 Type 2 certification ?

According to Rankiteo, Novartis Italia does not hold a SOC 2 Type 2 certification.

Does Novartis Italia comply with GDPR ?

According to Rankiteo, Novartis Italia is not listed as GDPR compliant.

Does Novartis Italia have PCI DSS certification ?

According to Rankiteo, Novartis Italia does not currently maintain PCI DSS compliance.

Does Novartis Italia comply with HIPAA ?

According to Rankiteo, Novartis Italia is not compliant with HIPAA regulations.

Does Novartis Italia have ISO 27001 certification ?

According to Rankiteo,Novartis Italia is not certified under ISO 27001, indicating the absence of a formally recognized information security management framework.

Which industry does Novartis Italia operate in ?

Novartis Italia operates primarily in the Pharmaceutical Manufacturing industry.

How many employees does Novartis Italia have ?

Novartis Italia employs approximately 506 people worldwide.

Does Novartis Italia own any subsidiaries ?

Novartis Italia presently has no subsidiaries across any sectors.

How many LinkedIn followers does Novartis Italia have ?

Novartis Italia's official LinkedIn profile has approximately 104,037 followers.

What is the NAICS classification code for Novartis Italia ?

Novartis Italia is classified under the NAICS code 3254, which corresponds to Pharmaceutical and Medicine Manufacturing.

Does Novartis Italia have a Crunchbase profile ?

No, Novartis Italia does not have a profile on Crunchbase.

Does Novartis Italia have a LinkedIn profile ?

Yes, Novartis Italia maintains an official LinkedIn profile, which is actively utilized for branding and talent engagement, which can be accessed here: https://www.linkedin.com/company/novartisitalia.

How many cybersecurity incidents has Novartis Italia experienced ?

As of August 22, 2026, Rankiteo reports that Novartis Italia has experienced 2 cybersecurity incidents.

How many peer or competitor companies does Novartis Italia have ?

Novartis Italia has an estimated 5,728 peer or competitor companies worldwide.

What types of cybersecurity incidents has Novartis Italia faced ?

Incident Types: The types of cybersecurity incidents that have occurred include Cyber Attack and Breach.

NEWRankiteo Cyber Underwriting Desktop - Score, price, and bind from your desktop

WindowsmacOSLinux

Download

Badge your company to reduce your risk score and your cyber insurance costs!

Link verified badges to your company page to build trust with insurers and customers.

Apply now and get your badge!

Internal validation & live display

Insurers and partners see a safer profile

Faster underwriting decisions

Trusted by insurers. Chosen by leaders.

Proud contributor to the Society of Actuaries.

Novartis Italia

Boost Score +25 with badge (5 left)

758

/1000

Fair

783

/1000

Fair

Novartis Italia Vendor Cyber Rating & Cyber Score

novartis.it

Add Your Compliance Badge

La nostra mission è scoprire nuovi modi per migliorare e prolungare la vita delle persone. Ci basiamo sull’ innovazione scientifica per affrontare le maggiori sfide in ambito sanitario: scopriamo e sviluppiamo trattamenti innovativi, identificando nuove modalità per far sì che raggiungano più persone possibili. Novartis ha sede a Basilea, in Svizzera. Le aziende del nostro Gruppo impiegano circa 125.000 collaboratori e i nostri prodotti sono disponibili in 155 Paesi in tutto il mondo. La capacità di attrarre, coltivare e mantenere i talenti è vitale per continuare a sviluppare prodotti innovativi in grado di offrire ai pazienti i migliori risultati. Leggi le linee guida della nostra community:

Novartis Italia A.I CyberSecurity Scoring

Scoring History

Novartis Italia

Novartis Italia CyberSecurity News & History

Past Incidents

Attack Types

Entity

Type

Severity

Impact

Seen

Blog Details

Supply Chain Source

Incident Details

View

Novartis

Breach

2/2026

NOV1774449180

Novartis Italia

Cyber Attack

100

06/2022

NOV21267722

Loading…

A.I.

Novartis Italia Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Actual

Prediction

Incident Predictions locked

Access Monitoring Plan

A.I Risk Score Likelihood 3 - 6 - 9 months

Actual

Prediction A

Prediction B

Prediction C

Prediction D

A.I. Risk Score Predictions locked

Access Monitoring Plan

Loading…

Underwriter Stats for Novartis Italia

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Novartis Italia in 2026.

Incidents vs All-Companies Average (This Year)

No incidents recorded for Novartis Italia in 2026.

Incident Types Novartis Italia vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Novartis Italia in 2026.

Incident History - Novartis Italia (X = Date, Y = Severity)

Loading…

SUBSIDIARY

Novartis Italia Subsidiaries

Novartis Italia

Pharmaceutical Manufacturing

Website: https://www.novartis.it/

Company Size: 506

NovartisPharmaceutical Manufacturing

Novartis USPharmaceutical Manufacturing

Novartis Gene TherapiesBiotechnology Research

Novartis SlovakiaPharmaceutical Manufacturing

Novartis SciencePharmaceutical Manufacturing

Novartis SlovakiaPharmaceutical Manufacturing

Novartis IndiaPharmaceutical Manufacturing

Novartis CanadaPharmaceutical Manufacturing

Novartis SlovakiaPharmaceutical Manufacturing

Novartis DeutschlandPharmaceutical Manufacturing

Novartis ColombiaPharmaceutical Manufacturing

Novartis PortugalPharmaceutical Manufacturing

Novartis SingaporePharmaceutical Manufacturing

Novartis MéxicoPharmaceutical Manufacturing

Novartis BrasilPharmaceutical Manufacturing

Novartis in SloveniaPharmaceutical Manufacturing

Novartis EspañaPharmaceutical Manufacturing

Novartis RomâniaPharmaceutical Manufacturing

Novartis US MedicalPharmaceutical Manufacturing

Novartis SlovakiaPharmaceutical Manufacturing

Novartis ArgentinaPharmaceutical Manufacturing

Novartis NorgePharmaceutical Manufacturing

Novartis Ireland Pharmaceutical Manufacturing

Novartis MagyarországPharmaceutical Manufacturing

Novartis FinlandPharmaceutical Manufacturing

Novartis Hong KongPharmaceutical Manufacturing

Novartis IsraelPharmaceutical Manufacturing

Novartis BeluxPharmaceutical Manufacturing

Novartis NederlandPharmaceutical Manufacturing

Novartis Nederland - OncologieGeneesmiddelenproductie

Novartis Nederland - NeurologieGeneesmiddelenproductie

Novartis Nederland - ReumatologieGeneesmiddelenproductie

Novartis Nederland - HematologieGeneesmiddelenproductie

Novartis Nederland - DermatologieGeneesmiddelenproductie

Novartis Nederland - Cardiovascular, Renal & Metabolism Geneesmiddelenproductie

Novartis DanmarkPharmaceutical Manufacturing

Novartis MedicalPharmaceutical Manufacturing

Novartis SlovakiaPharmaceutical Manufacturing

Novartis SerbiaPharmaceutical Manufacturing

Novartis SverigePharmaceutical Manufacturing

Novartis Gulf | نوفارتس الخليجPharmaceutical Manufacturing

Novartis, Australia & New ZealandPharmaceutical Manufacturing

Loading…

Novartis Italia Similar Companies

Servier

servier.com

Founded to serve health 70 years ago, Servier is a global pharmaceutical group governed by a non-profit Foundation that aspires to make a meaningful social impact for patients and for a sustainable world. The Group’s unique governance model preserves its independence and means it can fully serve its vocation of being committed to therapeutic progress to serve patient needs while adopting a long-term vision. Its employees are fully committed to this shared vocation, which serves as a source of inspiration every day. A world leader in cardiometabolism and venous diseases, Servier has made a major shift into oncology, which represents a new pillar of strategic growth. The Group devotes close to 70% of its R&D budget to this field, with the ambition of becoming a focused and innovative player in the development of treatments targeting rare cancers. Neurology will constitute a future growth driver. Servier is focusing on a limited number of diseases in this area where accurate patient profiling makes it possible to offer a targeted therapeutic response through precision medicine. To promote widespread access to quality care at a lower cost, the Group also offers a range of quality generic drugs covering most pathologies, leveraging well-known brands in France, and Eastern Europe. In all these areas, the Group takes patient considerations into account at every stage of the medicine life cycle. Headquartered in France, Servier relies on committed teams and strong geographical footprint; its medicines are available in close to 140 countries. In 2023/2024, the Group achieved sales revenue of €5.9 billion and EBITDA of €1.3 billion in 2024 (22.2%). Today, the Group employs over 22,000 people worldwide. -- To report a suspected adverse event with a Servier drug, please visit servier.com

EMS

cb ems.com.br

Fundada há mais de 60 anos e com capital 100% nacional, a EMS é a líder do mercado farmacêutico brasileiro há 19 anos consecutivos, pertencente ao Grupo NC, um dos maiores conglomerados brasileiros. A empresa ocupa também a liderança no segmento de genéricos desde 2013 (IQVIA 2019) e está entre os maiores laboratórios em preferência prescritiva no Brasil. Tem forte presença em PDVs de todo o país e atuação nas áreas de Prescrição Médica, Genéricos, Marcas, OTC e Hospitalar, fabricando medicamentos para praticamente todas as especialidades da Medicina. Possui fábricas em Hortolândia (SP), Manaus (AM), Brasília (DF) e Jaguariúna (SP). A EMS apoia ações de responsabilidade social dentro e fora do Brasil. Em 2017, por exemplo, o laboratório fechou parceria com a Organização Mundial da Saúde (OMS) para doar 100% do medicamento para erradicar, nos próximos anos, em todo o planeta, a bouba, doença negligenciada. A EMS é a única farmacêutica no mundo a ter abraçado essa causa. O Centro de Pesquisa & Desenvolvimento da EMS no Brasil é o mais moderno da América Latina. Na Itália, a EMS tem o laboratório de pesquisas MonteResearch. O foco de atuação do laboratório é a inovação nas seguintes frentes: inovação incremental; genéricos de alta complexidade; medicamentos biotecnológicos, por meio da empresa Bionovis; e inovação disruptiva, por meio da Brace Pharma, empresa da EMS instalada em 2013 nos Estados Unidos. Ainda, nos EUA, por meio de sua controlada Vero Biotech, localizada em Atlanta, Geórgia, a EMS, recentemente, obteve a aprovação de seu primeiro produto revolucionário submetido à FDA (Food and Drug Administration), posicionando o laboratório como uma empresa de inovação no mercado global. Com aportes frequentes em infraestrutura fabril e em pesquisa de ponta para desenvolver produtos inovadores, eficazes e seguros, a EMS, que já exporta para mais de 40 países, está preparada para continuar cuidando das pessoas que querem viver cada vez mais e melhor.

PT Kalbe Farma, Tbk

kalbe.co.id

Established in 1966, PT Kalbe Farma Tbk. (“the Company” or “Kalbe”) has gone a long way from its humble beginnings as a garage-operated pharmaceutical business in North Jakarta. It has expanded by strategic acquisitions of pharmaceutical companies, building a leading brand positioning and reaching to international markets to transform itself into an integrated consumer health and nutrition enterprise to promote its mission to improve health for a better life. Kalbe expands its business interests and transformed itself to become a provider of an integrated healthcare solution through its 4 business divisions: the Prescription Pharmaceutical Division, Consumer Health Division, Nutritionals Division and Distribution and Logistics Division. These business divisions manage an extensive portfolio of prescription pharmaceuticals and OTC drugs, energy drink and nutrition products, as well as a robust distribution arm serving over one million outlets across Indonesia’s vast archipelago. In the international market, the Company has established its footprint in ASEAN countries, Nigeria, and South Africa, positioning Kalbe as a national pharmaceutical company with a competitive edge in the export market. Kalbe Farma has established a robust research and development activities in leading edge generic drug formulation and continuous development of innovative consumer and nutritional products. Through strategic alliances with international partners, Kalbe have also started to support several successful research and development venture working on cancer drugs, stem cells and biotechnology research. With 17,000 employees, Kalbe Farma is the largest healthcare provider in Indonesia, with unrivaled marketing, branding, distribution, financial strength and research and development expertise. Kalbe Farma is also the largest publicly-listed pharmaceutical company in Southeast Asia, commanding a market capitalization of Rp71.0 trillion and sales turnover Rp21.0 trillion by end of 2018.

Lupin

lupin.com

Lupin Limited is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. Lupin specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Trusted by healthcare professionals and consumers globally, the company enjoys a strong position in India and the U.S. across multiple therapy areas, including respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women’s health. Lupin has 15 state-of-the-art manufacturing sites and 7 research centers globally, along with a dedicated workforce of over 23,000 professionals. Lupin is committed to improving patient health outcomes through its subsidiaries – Lupin Diagnostics, Lupin Digital Health, and Lupin Manufacturing Solutions.

MSD

msd.com

At MSD, known as Merck & Co., Inc., Rahway, NJ, USA in the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities. For more information, visit www.msd.com and connect with us on Facebook, Instagram, Twitter, and YouTube.

MANKIND PHARMA LTD

mankindpharma.com

Mankind Pharma, one of the top 5 leading pharmaceutical companies in India, started its journey in 1995. Today, we have an employee base of over 20,000 and are racing towards $1 Billion. At Mankind, we aspire to aid the community in leading a healthy life by formulating, developing, commercializing, and delivering affordable and accessible medicines that satisfy urgent medical needs. We take great pride in the success of our products ranging from Pharma, OTC and FMCG brands like Manforce Condoms, Manforce Tablets, Manforce Staylong Gel, Unwanted 72, Prega News, Gas-O-Fast, Kaloree 1, Kabzend, Acne Star Gel and many others. Our operations are in 34 overseas destinations across Asia, Africa, South-East Asia, Gulf countries and CIS countries. Our Vision - To be a global pharmaceutical company, most admired for its Affordability, Quality and Accessibility of products. Our Mission - To be able to provide cost-effective, innovation based superior quality pharmaceutical products across the globe, to improve the lives of the patients. Mankind strongly believes and follows its Core Values: 𝐂𝐮𝐬𝐭𝐨𝐦𝐞𝐫 𝐂𝐞𝐧𝐭𝐫𝐢𝐜𝐢𝐭𝐲: Commitment to Customer - Internal and External 𝐐𝐮𝐚𝐥𝐢𝐭𝐲: It is in our DNA to maintain and deliver highest quality standards and products 𝐈𝐧𝐧𝐨𝐯𝐚𝐭𝐢𝐨𝐧: Intensely Research driven organization aiming at product innovation and technology improvements 𝐈𝐧𝐭𝐞𝐠𝐫𝐢𝐭𝐲: Always trustworthy, widely respected to be honest, and believed by everyone 𝐆𝐨 𝐁𝐞𝐲𝐨𝐧𝐝: Aim higher than capabilities 𝐏𝐞𝐨𝐩𝐥𝐞 𝐃𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭 𝐚𝐧𝐝 𝐂𝐨𝐥𝐥𝐚𝐛𝐨𝐫𝐚𝐭𝐢𝐨𝐧: Together we are foreseeing future and diligently stimulating our people in attaining goals

Hikma Pharmaceuticals

cb hikma.com

For almost 50 years, we’ve been creating high-quality medicines and making them accessible to the people who need them. We are a trusted, reliable partner and dependable source of over 800* high-quality generic, specialty and branded pharmaceutical products that hospitals, physicians and pharmacists need to treat their patients across North America, MENA and Europe. We have 29 manufacturing plants, 3 R&D hubs and c9,500 employees worldwide. *As of December 2025 Subscribe to our channel on YouTube https://youtube.com/@hikmapharmaceuticals5668 For all product information and enquiries, please contact us at [email protected]

Glenmark Pharmaceuticals

glenmarkpharma.com

Glenmark Pharmaceuticals Limited is a research-led, global organization committed to enriching lives. Innovation is deeply embedded in Glenmark’s culture; it is how we differentiate ourselves in our key markets and create greater value for our stakeholders. In our journey of innovation over the past four and a half decades, we have evolved from a generics company to a global organization offering specialty and branded products. Glenmark’s core values of Achievement, Respect, and Knowledge impart a sense of organizational unity that drives our growth. We have established a robust global branded generics, specialty, and OTC business; with a significant presence in the therapy areas of dermatology, respiratory, and oncology. Our ten state-of-the-art manufacturing facilities spread across four continents with operations in over 80 countries help us impact millions of patients across the globe. We recently consolidated our innovation efforts in small molecules and biologics research with the formation of ‘Ichnos Glenmark Innovation’ (IGI). This alliance is aimed at leveraging the capabilities of Glenmark and its subsidiary, Ichnos Sciences, to accelerate innovation in cancer treatment. To know more about IGI, check out: https://iginnovate.com/ Sustainability is an integral aspect of all our operations and we are focused on achieving our Environment, Social and Governance (ESG) goals. Our responsibility also extends to our communities, and over the years, our CSR efforts have touched the lives of over 3 million people.

AbbVie

cb abbvie.com

AbbVie is a global biopharmaceutical company focused on creating medicines and solutions that put impact first — for patients, communities, and our world. We aim to address complex health issues and enhance people's lives through our core therapeutic areas: immunology, oncology, neuroscience, aesthetics and other areas of unmet need. Learn more about us at www.abbvie.com and review our community guidelines at https://www.abbvie.com/social-media-community-guidelines.html.

Loading…

NEWS

Novartis Italia CyberSecurity News

Latest updates, reports, and threat intel affecting the global network.

June 06, 2024 07:00 AM

Novartis, Roche unit and others face Italy antitrust probe over eye drug

Italy's antitrust regulator said on Thursday it had launched an investigation into pharmaceutical companies including Novartis and...

Read Article

Loading…

CVE

Latest

Global CVEs (Not Company-Specific)

CVE-2026-53541

SUMMARY

OliveTin gives access to predefined shell commands from a web interface. The `filterToDefinedArgumentsOnly` function in the executor is intended to discard any arguments not explicitly defined in the action's configuration. However, prior to commit ebffd9f040f791208aee1db2e5a8aecd1e3e603d, a special case allows any argument whose name starts with `ot_` to bypass this filter. While two system arguments (`ot_executionTrackingId` and `ot_username`) are injected by OliveTin and overridden, all other `ot_`-prefixed arguments supplied by the user pass through unmodified. These bypassed arguments are not type-checked — the validation loop only iterates over the action's defined arguments, so `ot_`-prefixed arguments skip all type safety checks entirely; set as environment variables — via `buildEnv()`, with completely unvalidated values, and passed to the executed command; and included in the template context — available as `.Arguments.ot_*` in template rendering. Commit ebffd9f040f791208aee1db2e5a8aecd1e3e603d contains a patch.

Published

Date2026-08-21

Updated

Date2026-08-21

RISK INFORMATION (Score: 4.3)

cvss3

Base Score: 4.3

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:N/I:L/A:N

Impact Score

1.4

Exploitability

2.8

REFERENCES

CVE-2026-53525

SUMMARY

WeeChat (Wee Enhanced Environment for Chat) is a free chat client. In versions 0.3.1 through 4.9.0, the WeeChat relay authentication uses non-constant-time string comparison functions (weechat_strcasecmp and strcmp) to verify password hashes and plaintext passwords. An attacker can exploit timing differences to extract the server-computed hash character by character, then authenticate using the correct hash without knowing the password. Version 4.9.1 fixes the issue.

Published

Date2026-08-21

Updated

Date2026-08-21

RISK INFORMATION (Score: 7.4)

cvss3

Base Score: 7.4

Complexity: HIGH

CVSS:3.1/AV:N/AC:H/PR:N/UI:N/S:U/C:N/I:H/A:H

Impact Score

5.2

Exploitability

2.2

REFERENCES

https://github.com/weechat/weechat/security/advisories/GHSA-vhv8-g2r9-cwcc

CVE-2026-53524

SUMMARY

WeeChat (Wee Enhanced Environment for Chat) is a free chat client. In versions 4.3.0 through 4.9.0, the WeeChat relay module's WebSocket permessage-deflate decompression function relay_websocket_inflate() has no upper bound on output size. An authenticated relay user can send a small compressed WebSocket frame (~100 bytes) that decompresses to gigabytes, exhausting all server memory and crashing the entire WeeChat process. The api protocol enables permessage-deflate and requires authentication before WebSocket upgrade. Version 4.9.1 patches the issue.

Published

Date2026-08-21

Updated

Date2026-08-21

RISK INFORMATION (Score: 6.5)

cvss3

Base Score: 6.5

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:N/I:N/A:H

Impact Score

3.6

Exploitability

2.8

REFERENCES

https://github.com/weechat/weechat/security/advisories/GHSA-v2v4-45wm-5cr3

CVE-2026-53499

SUMMARY

FORT Validator is a Resource Public Key Infrastructure (RPKI) relying-party validator that produces validated route-origin data. FORT Validator versions through 1.6.7 contain an origin-validation error in their RRDP processing: a delegated CA under the same Trust Anchor Locator (TAL) can reference a victim CA’s public RRDP notification and snapshot URLs, causing FORT’s URL-based download cache to report success after deleting the victim’s local snapshot. Following a routine victim publication, this can silently remove the victim’s VRPs and other signed objects from FORT’s output, potentially enabling route hijacking or loss of reachability. Version 1.6.8 contains a patch that rejects cross-origin RRDP snapshot and delta URLs; as a workaround, administrators can disable HTTP/RRDP with --http.enabled=false while keeping rsync enabled, although this can leave data unavailable or stale where rsync is not supported.

Published

Date2026-08-21

Updated

Date2026-08-21

RISK INFORMATION (Score: )

cvss4

Base Score: 7.2

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:P/PR:L/UI:N/VC:N/VI:H/VA:L/SC:N/SI:H/SA:H/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

Exploitability

REFERENCES

https://github.com/NICMx/FORT-validator/security/advisories/GHSA-qfm3-577x-rh54

CVE-2026-49360

SUMMARY

Recce is a data-validation toolkit for enhanced dbt (data build tool) PR review. Prior to version 1.50.0, OSS server deployments that expose the server to an untrusted network without authentication are vulnerable to unauthenticated SQL execution through the query run API. When Recce is configured with a DuckDB-backed project, an attacker can use DuckDB filesystem primitives to read and write files accessible to the Recce server process. The impact depends on how Recce is deployed, but may include disclosure of local files, tampering with Recce/dbt artifacts, modification of browser-served static files leading to stored XSS, and modification of application files if those paths are writable. If Recce is run as root, file access occurs with root privileges inside that host or container. This issue has been patched in Recce `v1.50.0`. Users should upgrade to Recce `v1.50.0` or later. The patch restricts unsafe file read/write behavior for DuckDB-backed query execution and hardens the affected query path. Other warehouse adapters have also been reviewed for similar exposure. Users who cannot upgrade immediately should avoid exposing `recce server` to the public internet or any untrusted network. Recommended mitigations include enabling authentication or placing Recce behind an authenticated reverse proxy/VPN, running Recce as a non-root user, using a read-only application filesystem where possible, and ensuring that sensitive files or credentials are not available to the Recce process.

Published

Date2026-08-21

Updated

Date2026-08-21

RISK INFORMATION (Score: )

cvss4

Base Score: 7.8

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:L/VI:L/VA:L/SC:L/SI:H/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

Exploitability

REFERENCES

Loading…

API

Access Data Using Our API

Get company history

curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'

Try It API Documentation Rapid

MEASURE

What Do We Measure ?

Incident

Finding

Grade

Digital Assets

Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.

These are some of the factors we use to calculate the overall score:

Network SecurityIdentify exposed access points, detect misconfigured SSL certificates, and uncover vulnerabilities across the network infrastructure.

SBOM (Software Bill of Materials)Gain visibility into the software components used within an organization to detect vulnerabilities, manage risk, and ensure supply chain security.

CMDB (Configuration Management Database)Monitor and manage all IT assets and their configurations to ensure accurate, real-time visibility across the company's technology environment.

Threat IntelligenceLeverage real-time insights on active threats, malware campaigns, and emerging vulnerabilities to proactively defend against evolving cyberattacks.

Rankiteo

By Rankiteo

★ ★ ★ ★ ★

View on G2.com

Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.

View latest plans →View all security reports →

MILESTONEG

Users
Love Us

Loading…